Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2008-01-18
2010-12-07
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C514S108000
Reexamination Certificate
active
07846474
ABSTRACT:
This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.+−.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables.
REFERENCES:
patent: 5403829 (1995-04-01), Lehtinen et al.
patent: 5409911 (1995-04-01), Tyler et al.
patent: 6864228 (2005-03-01), Roldan et al.
Thiebaud et al., 1997, The American Journal of Medicine, vol. 103, pp. 298-307.
Glorieux, F.H. et al.:“Cyclic administration of pamidronate in children with severe osteogenesis imperfecta”, New England Journal of Medicine, the Massachusetts Medical Society, Waltham, vol. 14, No. 339, Jan. 10, 1998, pp. 947-952.
Astrom, E. et al.:“Beneficial effect of bisphosphonate during 5 years of treatment of severe osteogenesis imperfecta”, Abstract & Acta Pediatricia, vol. 87, No. 1, Jan. 1998, pp. 64-68.
Landsmeer-Beker, E.A. et al.:“Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)”, European Journal of Pediatrics, Springer Verlag, XX, vol. 156, No. 10, 1997, pp. 792-794.
Devogelaer, J.P. et al.:“Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta”, Abstract & Skeletal Radiology, vol. 16, No. 5, 1987,pp. 360-363.
Roldan, Emilio J.A. et al.:“Bisphosphonates in Children with Osteogenesis Imperfecta may improve Bone Mineralization but not Bone Strength. Report of Two Patients.” Journal of Pediatric Endocrinology & Metabolism, vol. 12, No. 4, 1999, pp. 555-559.
Bembi, B. et al.:“Intravenous pamidronate treatment in osteogenesis imperfecta”, The Journal of Pediatrics, Oct. 1997, vol. 131, No. 4, pp. 622-625.
Plotkin, Horacio et al.:“Medical Treatment of Osteogenesis Imperfecta”, Drug Development Research, vol. 49, Issue 3, 2000, pp. 141-145.
Fujiwara, I. et al.:“Intravenous pamidronate treatment in osteogenesis imperfecta”, Eur J pediatrics, 1998, 157:261-262.
Devogelaer, J.P. et al.:“Use Of Pamidronate In Chronic And Acute Bone Loss Conditions”. Medicina (B. Aires) 1997, 57 (suppl.1):101-108.
Plotkin, Horacio et al.:“Pamidronate Treatment Of Severe Osteogenesis Imperfecta in Children under 3 Years of Age”. The Journal of Clinical Endocrinology & Metabolism, 2000, 85:1846-1850.
Glorieux, Francis H. et al.: “Bisphosphonate Therapy for Severe Osteogenesis Imperfecta”, Journal of Pediatric Endocrinology & Metabolism, 2000, 13 (suppl. 2):989-992.
Thiebaud, D. et al.: “Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis”. The American Journal of Medicine, 1997, vol. 103, pp. 298-307.
Perez-Lloret Anibal
Roldan Emilio J.A.
Gador S.A.
Patent Central LLC
Pendorf Stephan A.
Teller Roy
Tsang Cecilia
LandOfFree
Use of bisphosphonates for the treatment of osteogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bisphosphonates for the treatment of osteogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bisphosphonates for the treatment of osteogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164433